Summary
The efficacy of once-daily bopindolol, a nonselectiveβ-adrenoceptor blocking agent with partial agonist activity, and of pindolol and atenolol in the treatment of essential hypertension has been compared. 369 patients were investigated in a double-blind parallel-group study. The treatment period was 10 weeks. Blood pressure normalisation (diastolic BP equal to or less than 90 mmHg) was to be achieved by a stepwise increase in the dose of the test drugs, and, if required, by addition of a diuretic. Normalisation of blood pressure was achieved in 71 to 76% of the subjects, with no significant differences between bopindolol, pindolol, and atenolol. Special attention was given to evaluation of side effects by using two methods for registration of all adverse events during the study. A low incidence of drug-induced side effects was observed, with no significant difference between bopindolol, pindolol, and atenolol. There was no evidence of unsuspected adverse reactions due to bopindolol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McDevitt DG (1979) Adrenoceptor blocking drugs: clinical pharmacology and therapeutic use. Drugs 17: 267–288
Opie LH (1980) Drugs and the heart. I. Beta-blocking agents. Lancet 1: 693–698
Petrie JC, Jeffers TA, Robb OJ, Scott AR, Webster J (1980) Atenolol, sustained-release oxprenolol and long acting propranolol in hypertension. Br Med J 281: 1573–1574
Bühler FR, Bertel O, Lütold BE (1978) Simplified and age-stratified antihypertensive therapy based on beta-blockers. Cardiovasc Med 3: 135–148
Berthold R, Waite R, Weber H (1981) Pharmacological studies with bopindolol: a new long actingβ-adrenoceptor antagonist. Br J Pharmacol 75: 829 P
Aellig WH (1982) Clinical pharmacological experiments with bopindolol (LT 31–200): a long actingβ-adrenoceptor blocking drug with partial agonist activity. Br J Clin Pharmacol 13: 267P-268P
Brummelen P van, Buehler FR, Amann FW, Bolli P (1982) Effects of a new long-acting beta-blocker bopindolol (LT 31–200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension. Eur J Clin Pharmacol 22: 491–493
Brummelen P van (1983) The relevance of intrinsic sympathomimetic activity forβ-blocker-induced changes in plasma lipids. J Cardiovasc Pharmacol 5: S51-S55
Simpson WT (1977) Nature and incidence of unwanted effects with atenolol. Postgrad Med J 53 [Suppl 3]: 162–167
Henningsen NC, Mattiasson I (1979) Long-term clinical experience with atenolol — a new selectiveβ-1-blocker with few side-effects from the central nervous system. Acta Med Scand 205: 61–66
Frishman W (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetik properties. Am Heart J 97: 663–670 Part 2. Physiologic and metabolic effects. Am Heart J 97: 797–807
Zerssen D v (1976) Die Befindlichkeits-Skala. Manual. Beltz Test GmbH, Weinheim, FRG
Finney DJ (1965) The design and logic at monitoring at drug news. J Chronic Dis 18: 77–98
Baumann U, Stieglitz RD (1980) Ein Vergleich von vier Beschwerdelisten. Arch Psychiatr Nervenkr 209: 145–163
Mann S, Millar Graig MW, Balasubramanian V, Rattery EB (1981) Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment. Br J Clin Pharmacol 12: 223–228
England JDF (1981) Beta-adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol. Aust NZ J Med 11: 35–40
Bulpitt CJ, Dollery CT (1973) Side-effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J 3: 485–490
Skegg DCG, Doll R (1977) The case for recording events in clinical trials. Br Med J 2: 1523–1524
Simpson RJ, Tiplady B, Skegg DCG (1980) Event recording in a clinical trial of a new medicine. Br Med J 1: 1133–1134
Norwegian multicenter study group (1981) Timolol-induced reduction in mortality and reinfarction in patients-surviving acute myocardial infarction. N Engl J Med 304: 801–807
Medical research council working party on mild to moderate hypertension (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 1: 539–543
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schiess, W., Welzel, D. & Gugler, R. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol 27, 529–534 (1984). https://doi.org/10.1007/BF00556887
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00556887